Replimune Group, Inc.
REPL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737953
In the last 90 days, Replimune Group, Inc. insiders filed 0 open-market purchases and 5 sales; 199 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Replimune Group, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 106 | 135 | +29 |
| Shares | 40.8M | 48.2M | +7.43M (+18.2%) |
| Value | $703.9M | $1.31B | +$606.5M (+86.2%) |
New holders (33)
Institutions that held Replimune Group, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (4)
Institutions that held Replimune Group, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Great Point Partners LLC | 390,000 | $6.74M |
| Two Sigma Investments, LP | 84,634 | $1.46M |
| Engineers Gate Manager LP | 10,566 | $182.0K |
| Point72 Hong Kong Ltd | 3,252 | $56.0K |